The following are excerpts from the newslette
- Lesson from Denver: look beyond
blaming individuals for errors
- A case riddled with latent and active failures
- Safety Briefs
- Potential for confusion between Proleukin® (aldesleukin)
and the new platelet growth factor product, Neumega®
(oprelvekin) because of synonyms.
- Reports of mix-ups between premixed heaprin bags and
DuPont Pharma's Hespan.
- Wyeth-Ayerst has revised Duract® labeling to
include a boxed warning about severe hepatic reactions.
- FDA alerts MedWatch partners about interchangeability
of 'narrow therapeutic index" drugs
- Lilly just launched Evista (raloxifene) for prevention
of osteoporosis in postmenopasual women. Watch out for
mixup with E-vista® a brand of injectable hydroxyzine
that was recently withdrawn by the manufacturer.
- Upcoming industry seminar: The Pharmaceutical Industry's
Role in Preventing Drug Product-Related Medication Errors.
April 3, 1998
- It's not too late for one more
New Year's resolution
- Adding food color to enteral feedings-an unnecessary risk?
- Safety Briefs
- FDA is warning about severe cardiovascular adverse
drug events, serious drug interactions and rare reports
of anaphylaxis with Hismanal®
- In Nursing97 Drug Handbook published by Springhouse
Corp. there is an error in the monograph for pyridostigmine
bromide on page 519. The text states "for IM or IV use,
1/3 of oral dosage is given." It should read ". 1/30
of oral dosage is given."
- HCFA's proposed zero tolerance for serious medication
errors has already taken its toll.
- The Latiolais Leadership Program at Ohio State University
is conducting a forum on April 19th to evaluate the
barriers to voluntary reporting of adverse drug events.
- It goes without saying that the first step of ordering
treatments in a hospital should be matching the patient's
name to the name on the computer screen or to the addressograph
stamped on the order sheet.
- A letter published this past week in Lancet warns
of the risk of severe mucocutaneous adverse reactions
associated with nevirapine (ViramuneŇ) in HIV patients
(Warren KJ et al. Nevirapine-associated Stevens-Johnson
syndrome. Lancet 1998;351:567).
- Now that the 5HT1 agonist zolmitriptan (Zomig®)
has been marketed, be on the lookout for mix-ups with
- · We often advise that pharmacy computer systems should
have warnings for dose maximums, especially for chemotherapy.
Another valuable warning that computer systems should
have is for medications absolutely contraindicated in
pregnancy, such as angiotensin II antagonists and ACE
- Do you provide the same level of care for healthcare
providers with medical conditions as you do other patients?
Specifically, do you counsel them about their medications?
In a recent report, a dispensing error occurred that
would have been noticed during counseling, but the patient,
a retired pharmacist, was not counseled